Puma Biotechnology falls more than 20%
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology: Still Bullish At These Prices (NASDAQ:PBYI) | Seeking Alpha
Exhibitor Puma Biotechnology 11-6 - Scripps CME Connection
Puma Biotechnology Surging
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Is Puma Biotechnology (PBYI) Stock a Solid Choice Right Now?
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: A Speculative Investment At A Discount (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business
Is Puma Biotechnology a Buy? | The Motley Fool
What Happened To Puma Biotechnology?
Puma Biotechnology
Puma Biotechnology
Puma Bio FDA Advisory Panel Live Blog - TheStreet
PUMA BIOTECHNOLOGY, INC. FORM 8-K/A - Shareholder.com
Puma Biotechnology: Too Little, Too Late, Too Much Of A Bad Side Effect (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Former Puma Biotech Executive Gets U.S. Prison Term for Insider Trading
Puma Biotechnology (PBYI) Stock Climbs On Orphan Drug Designation | Alpha Stock News
PharmaShots - Incisive news in 3 shots on Twitter: "Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer https://t.co/KKTvnp68jJ https://t.co/LR02TGd4oT" / Twitter
Puma Biotechnology Profile | FDA Health News
